“Eli Lilly Conference Call Summary [2022-12-13]”, 2022-12-13 ():
Lilly announced on their conference call today that the triple agonist (GLP-1, GIP, Glucagon) retatrutide achieved 22–24% weight loss at 48 weeks with a similar tolerability profile to tirzepatide. They are moving forward with phase 3 for obesity…Lilly believes they can achieve a step function increase of >5% weight loss over tirzepatide in the phase 3 trial. That would push average weight loss to >27%.
Lilly also talked about the phase 2 results for their daily oral GLP-1, orforglipron. It achieved 15% weight loss in 36 weeks. They are moving it to phase 3.
Interestingly, they mentioned they may not move forward with the phase 3 trial for diabetes. They haven’t ruled it out, but it doesn’t seem to achieve better glucose control or A1C reductions over tirzepatide. However, they still believe anyone with obesity and T2D will be able to benefit greatly from this drug.